about
Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trialsPreventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromesRisk factors, hospital management and outcomes after acute myocardial infarction in South Asian Canadians and matched control subjects.Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages.Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference.Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update.Rationale and design of South Asian Birth Cohort (START): a Canada-India collaborative study.Access to cardiac rehabilitation among South-Asian patients by referral method: a qualitative study.Clinical characteristics of South Asian patients hospitalized with heart failure.Is South Asian ethnicity an independent cardiovascular risk factor?South Asians and cardiovascular risk: what clinicians should know.Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.Effectiveness of inpatient and outpatient strategies in increasing referral and utilization of cardiac rehabilitation: a prospective, multi-site study.The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients.Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality.A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.Evidence for the efficacy of ARBs across the cardiovascular continuum.Effect of cardiac rehabilitation referral strategies on utilization rates: a prospective, controlled study.Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group.Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS.Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction.2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.Impactful clinical trials of 2012: what clinicians need to know.Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials.Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease.Canadian Cardiovascular Society position statement on familial hypercholesterolemia.Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology/Canadian Society of Cardiac Surgery position statement on revascularization--multivessel coronary artery disease.Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.Ethnic and diet-related differences in the healthy infant microbiome.Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9.2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.Harmonization of Food-Frequency Questionnaires and Dietary Pattern Analysis in 4 Ethnically Diverse Birth Cohorts.Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study.ACE inhibitors: back to prime time?
P50
Q26782970-F373B660-45FD-4613-8A91-F5CEC3BE91FAQ28194374-AC815899-732B-49E6-BCAE-7505C20113D4Q34011233-04C4321C-EA9A-4E57-BA3C-7BFAA2E8FC3FQ34150591-0BB0F0F4-5824-4B6B-AE0B-20440B43DA2AQ34220626-E4532D9E-8E9E-47C9-84C0-3632524CD444Q34387237-315C38A4-C25F-467E-AE4C-1D1C3F680D9BQ34565563-29BB12B4-CE43-4FDE-8AD6-6B19F2B44055Q35705365-1BEB572A-6312-4BA7-9D42-295F012A1D24Q36301526-0C80EB89-D014-4AB3-A009-0CA52B90E3B8Q36415344-C0CA6D95-75D2-4886-A6F3-4261AAA20729Q36519684-B43AF9C6-93BE-4250-BB67-55EC613772F9Q36519924-C6973C33-3C22-4F98-8DAB-36AC9BD1CA50Q36521300-4DBECFD1-1106-4A48-880C-7B9FDAFDF762Q36768458-B56C5CB8-0445-4984-96C1-6AECDE82EF6AQ36877056-5372C9FF-EC1A-46E4-A44E-F56A9FF1A064Q37098328-27F1970C-9926-41A7-944D-3ED94BD3DD3CQ37435149-65B5E09C-AF48-4D51-A649-8E5C8F7059CCQ37466366-638A4EDA-41E5-48D2-B12F-E731B283476FQ37714919-0BF23A22-357C-4097-B5F1-2498293E1342Q37843053-F59EBE62-6628-4958-B114-9C87361F641CQ37860653-F73497DC-BA83-4CD4-8C5E-18090F8E4B8BQ37860655-B143DD74-28F5-45A4-87DA-EBEACEDD73DBQ37961084-F944089B-6EC9-423A-B098-0C7EBC16F9A2Q37961085-0A42BCB5-3B9C-4530-B32D-73482EA0594EQ38076875-F537246C-9460-4275-B883-CD13A71CCC0BQ38108981-D989B5B0-41F9-437F-8D5C-535CEF0E51ECQ38195447-2097FB15-3332-4BE9-AC9E-8EF3EB5A62A4Q38234223-F017189C-495C-49C2-9C12-F9C65D0BE6B6Q38275368-A372E693-88CD-4490-9254-58801AAC833AQ38283184-9058DF48-936C-453B-81BB-8529CAFD5886Q38721471-DC28E7ED-FE34-4600-A993-53AA1A4F9F6DQ38737986-B2338604-A1F1-4797-9E2C-9FDB6E3F90CEQ38876388-1EE2D019-3320-4AD9-B680-9BC9485D02E4Q38927380-8D8ED9CC-35F8-418A-AF35-1E3116D19764Q38974082-3C8C4093-A809-4202-B2F6-3E972DB188DFQ39318852-CA8F6C4D-AFD1-4A29-8DA8-76AA670FE823Q40224775-A786BD3D-A6B7-4A6D-86B0-FF372ECD598CQ40780170-46B10692-650A-4B17-9EE9-26896A97B140Q42367700-9883C9A6-596A-478F-903B-4BFD24AC5475Q42409973-12069DB0-E5D1-4A91-9838-AB765D6BA8BF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Milan Gupta
@ast
Milan Gupta
@en
Milan Gupta
@es
Milan Gupta
@fr
Milan Gupta
@nl
Milan Gupta
@sl
type
label
Milan Gupta
@ast
Milan Gupta
@en
Milan Gupta
@es
Milan Gupta
@fr
Milan Gupta
@nl
Milan Gupta
@sl
prefLabel
Milan Gupta
@ast
Milan Gupta
@en
Milan Gupta
@es
Milan Gupta
@fr
Milan Gupta
@nl
Milan Gupta
@sl
P106
P21
P31
P496
0000-0002-7385-9006
P569
2000-01-01T00:00:00Z